Evaluation of Expression Profiles of Hematopoietic Stem Cell, Endothelial Cell, and Myeloid Cell Antigens in Spontaneous and Chemically Induced Hemangiosarcomas and Hemangiomas in Mice

Toxicologic Pathology

Volumn 41, Issue 5, 2013, Pages 709-721

  Kakiuchi Kiyota, Satoko ^a,b   Crabbs, Torrie A ^c   Arnold, Lora L ^a   Pennington, Karen L ^a   Cook, Jon C ^b   Malarkey, David E ^d   Cohen, Samuel M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

endothelial progenitor cells; hemangiomas; hemangiosarcomas; hematopoietic stem cells; immunohistochemistry; mouse

Indexed keywords

CD14 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CELL ANTIGEN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELLS; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HEMANGIOMA; HEMATOPOIETIC STEM CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; VASCULAR TUMOR;

ENDOTHELIAL PROGENITOR CELLS; HEMANGIOMAS; HEMANGIOSARCOMAS; HEMATOPOIETIC STEM CELLS; IMMUNOHISTOCHEMISTRY.; MOUSE;

ANIMALS; ANTIGENS, CD; BIOLOGICAL MARKERS; ENDOTHELIAL CELLS; FEMALE; HEMANGIOMA; HEMANGIOSARCOMA; HEMATOPOIETIC STEM CELLS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MUTAGENS; MYELOID CELLS;

MUS;

EID: 84879482840     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623312464309     Document Type: Article

References (40)

1. Breiteneder-Geleff S. Soleiman A. Kowalski H. Horvat R. Amann G. Kriehuber E. Diem K. Weninger W. Tschachler E. Alitalo K. Kerjaschki D. (1999). Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154, 385–94.
2. Case J. Mead L. E. Bessler W. K. Prater D. White H. A. Saadatzadeh M. R. Bhavsar J. R. Yoder M. C. Haneline L. S. Ingram D. A. (2007). Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 35, 1109–18.
3. Cohen S. M. Storer R. D. Criswell K. A. Doerrer N. G. Dellarco V. L. Pegg D. G. Wojcinski Z. W. Malarkey D. E. Jacobs A. C. Klaunig J. E. Swenberg J. A. Cook J. C. (2009). Hemangiosarcoma in rodents: Mode-of-action evaluation and human relevance. Toxicol Sci 111, 4–18.
4. Criswell K. A. Wojcinski Z. Pegg D. Herman J. Anderson T. Wesche D. Giddings J. Brady J. T. Cook J. C. (2012). Mode of action associated with development of hemangiosarcoma in mice given pregabalin and assessment of human relevance. Toxicol Sci 128, 57–71.
5. Donehower L. A. Harvey M. Slagle B. L. McArthur M. J. Montgomery C. A. Jr Butel J. S. Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215–21.
6. Duddy S. K. Parker R. F. Bleavins M. R. Gough A. W. Rowse P. E. Gorospe S. Dethloff L. A. de la Iglesia F. A. (1999). p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Toxicol Appl Pharmacol 156, 106–12.
7. Forton G. E. Van Parys G. Hertveldt K. (2005). Primary angiosarcoma of the non-irradiated parotid gland: A most uncommon, highly malignant tumor. Eur Arch Otorhinolaryngol 262, 173–77.
8. Gehling U. M. Ergun S. Schumacher U. Wagener C. Pantel K. Otte M. Schuch G. Schafhausen P. Mende T. Kilic N. Kluge K. Schafer B. Hossfeld D. K. Fiedler W. (2000). In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95, 3106–12.
9. Handgretinger R. Gordon P. R. Leimig T. Chen X. Buhring H. J. Niethammer D. Kuci S. (2003). Biology and plasticity of CD133+ hematopoietic stem cells. Ann N Y Acad Sci 996, 141–51.
10. Harach H. R. Jasani B. Williams E. D. (1983). Factor VIII as a marker of endothelial cells in follicular carcinoma of the thyroid. J Clin Pathol 36, 1050–54.
11. Hardisty J. F. Elwell M. R. Ernst H. Greaves P. Kolenda-Roberts H. Malarkey D. E. Mann P. C. Tellier P. A. (2007). Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists. Toxicol Pathol 35, 928–41.
12. Herman J. R. Dethloff L. A. McGuire E. J. Parker R. F. Walsh K. M. Gough A. W. Masuda H. de la Iglesia F. A. (2002). Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol Sci 68, 226–36.
13. Hermiston M.L. Xu Z. Weiss A. (2003). CD45: A critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21, 107–37.
14. Hollstein M. Marion M. J. Lehman T. Welsh J. Harris C. C. Martel-Planche G. Kusters I. Montesano R. (1994). p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 15, 1–3.
15. Hong H. L. Ton T. V. Devereux T. R. Moomaw C. Clayton N. Chan P. Dunnick J. K. Sills R. C. (2003). Chemical-specific alterations in ras, p53, and beta-catenin genes in hemangiosarcomas from B6C3F1 mice exposed to o-nitrotoluene or riddelliine for 2 years. Toxicol Appl Pharmacol 191, 227–34.
16. Hristov M. Weber C. (2004). Endothelial progenitor cells: Characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 8, 498–508.
17. Itakura E. Yamamoto H. Oda Y. Tsuneyoshi M. (2008). Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 97, 74–81.
18. Iwata J. Sonobe H. Furihata M. Ido E. Ohtsuki Y. (1996). High frequency of apoptosis in infantile capillary haemangioma. J Pathol 179, 403–408.
19. Kakiuchi-Kiyota S. Vetro J. A. Suzuki S. Varney M. L. Han H. Y. Nascimento M. Pennington K. L. Arnold L. L. Singh R. K. Cohen S. M. (2009). Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: Differences between human and mouse. Toxicol Appl Pharmacol 237, 83–90.
20. Kakiuchi-Kiyota S. Arnold L. L. Yokohira M. Koza-Taylor P. Suzuki S. Varney M. Pennington K. L. Cohen S. M. (2011a). Evaluation of direct and indirect effects of the PPARgamma agonist troglitazone on mouse endothelial cell proliferation. Toxicol Pathol 39, 1032–45.
21. Kakiuchi-Kiyota S. Arnold L. L. Yokohira M. Suzuki S. Pennington K. L. Cohen S. M. (2011b). Evaluation of PPARgamma agonists on rodent endothelial cell proliferation. Toxicology 287, 91–98.
22. Kanayasu-Toyoda T. Yamaguchi T. Oshizawa T. Hayakawa T. (2003). CD31 (PECAM-1)-bright cells derived from AC133-positive cells in human peripheral blood as endothelial-precursor cells. J Cell Physiol 195, 119–29.
23. Kim S. J. Kim J. S. Papadopoulos J. Wook Kim S. Maya M. Zhang F. He J. Fan D. Langley R. Fidler I. J. (2009). Circulating monocytes expressing CD31: Implications for acute and chronic angiogenesis. Am J Pathol 174, 1972–80.
24. Kuroda N. Hamaguchi N. Inoue K. Ohara M. Mizuno K. Hayashi Y. Lee G. H. (2009). Application of immunocytochemistry to the diagnosis of primary epithelioid angiosarcoma of the lung. Med Mol Morphol 42, 250–53.
25. Lamerato-Kozicki A. R. Helm K. M. Jubala C. M. Cutter G. C. Modiano J. F. (2006). Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol 34, 870–878.
26. Lin B. T. Weiss L. M. Battifora H. (1997). Intravascularly disseminated angiosarcoma: True neoplastic angioendotheliomatosis? Report of two cases. Am J Surg Pathol 21, 1138–1143.
27. Meis-Kindblom J. M. Kindblom L. G. (1998). Angiosarcoma of soft tissue: A study of 80 cases. Am J Surg Pathol 22, 683–97.
28. Naka N. Tomita Y. Nakanishi H. Araki N. Hongyo T. Ochi T. Aozasa K. (1997). Mutations of p53 tumor-suppressor gene in angiosarcoma. Int J Cancer 71, 952–55.
29. Peichev M. Naiyer A. J. Pereira D. Zhu Z. Lane W. J. Williams M. Oz M. C. Hicklin D. J. Witte L. Moore M. A. Rafii S. (2000). Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95, 952–58.
30. Poblet E. Gonzalez-Palacios F. Jimenez F. J. (1996). Different immunoreactivity of endothelial markers in well and poorly differentiated areas of angiosarcomas. Virchows Arch 428, 217–21.
31. Ritter M. R. Reinisch J. Friedlander S. F. Friedlander M. (2006). Myeloid cells in infantile hemangioma. Am J Pathol 168, 621–28.
32. Schatteman G. C. Awad O. (2004). Hemangioblasts, angioblasts, and adult endothelial cell progenitors. Anat Rec A Discov Mol Cell Evol Biol 276, 13–21.
33. Terada T. (2011). Angiosarcoma of the oral cavity. Head Neck Pathol 5, 67–70.
34. Urbich C. Dimmeler S. (2004). Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 95, 343–53.
35. von Beust B. R. Suter M. M. Summers B.A. (1988). Factor VIII-related antigen in canine endothelial neoplasms: An immunohistochemical study. Vet Pathol 25, 251–55.
36. Weiss S. W. Goldblum J. R. (2008). Malignant vascular tumors. In Enzinger and Weiss's Soft Tissue Tumors, 5th ed. (Weis S. W. Goldblum J. R., eds.), pp 703–32. Mosley Elsevier, China.
37. Yoder M. C. Mead L. E. Prater D. Krier T. R. Mroueh K. N. Li F. Krasich R. Temm C. J. Prchal J. T. Ingram D. A. (2007). Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109, 1801–809.
38. Yonemori K. Tsuta K. Ando M. Hirakawa A. Hatanaka Y. Matsuno Y. Chuman H. Yamazaki N. Fujiwara Y. Hasegawa T. (2011). Contrasting prognostic implications of platelet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. Ann Surg Oncol 18, 2841–50.
39. Zietz C. Rossle M. Haas C. Sendelhofert A. Hirschmann A. Sturzl M. Lohrs U. (1998). MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 153, 1425–33.
40. Zindy F. Nilsson L. M. Nguyen L. Meunier C. Smeyne R. J. Rehg J. E. Eberhart C. Sherr C. J. Roussel M. F. (2003). Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. Cancer Res 63, 5420–27.